

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1. (Cancelled)

2. (Currently Amended) A compound as claimed in claim 4-12 where Z is selected from pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzothienyl, indoliny, indolyl, azaindolyl, azaindoliny, benzodihydrofuranyl, benzodihydrothienyl, pyrazolopyrimidinyl, pyrazolopyrimidonyl, azaquinazolinyl, azaquinazolinoyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, thienopyrimidonyl, quinoliny, pyrimidinyl, pyrazolyl, quinazolinyl, quinazolonyl, pyrimidonyl, pyridaziny, triaziny, benzoxaziny, benzoxazinonyl, benzothiaziny, benzothiazinonyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzotriazolyl group; more preferably Z represents quinoliny, pyrimidinyl, quinazolinyl groups.

3. (Currently Amended) A compound of claim 4-12 wherein the substitutions on any substituent as claimed in claim 4-12 may be selected from hydroxyl, oxo, halo, thio, nitro, amino, cyano, formyl, alkyl, haloalkyl, perhaloalkyl, alkoxy, haloalkoxy, perhaloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl, alkoxy, alkenoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl,

LOHRAY ET AL.
Appl. No. Unknown
July 7, 2006

heterocycloalkyl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, heterocyclyloxy, heterocyclylalkoxy, heterocyclylalkoxyacyl, acyl, acyloxy, acylamino, monosubstituted or disubstituted amino, arylamino, aralkylamino, carboxylic acid and its derivatives such as esters and amides, carbonylamino, hydroxyalkyl, aminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, arylthio, alkylsulfonylamino, aminocarbonylamino, alkylaminocarbonylamino, alkoxyamino, hydroxyl amino, sulfonyloxy, alkylsulfonyloxy, alkoxycarbonylamino, aryloxycarbonylamino, aralkyloxycarbonylamino sulfenyl derivatives, sulfonyl derivatives, sulfonic acid and its derivatives.

4. (Currently Amended) A compound of claim 4-12 selected from

2-(3-Amino-3-{4-[2-(2,2-dimethyl-cyclopropyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-4-methyl-pentanoic acid hydroxyamide;

2-(3-Amino-3-[4-(2-methoxymethyl-quinolin-4-ylmethoxy)-phenyl]-2-oxo-pyrrolidin-1-yl)-4-methyl-pentanoic acid hydroxyamide;

2-(3-Amino-3-[4-(2-methoxymethyl-quinolin-4-ylmethoxy)-phenyl]-2-oxo-pyrrolidin-1-yl)-N-hydroxy-propionamide;

N-Hydroxy-2-{3-[4-(2-methoxymethyl-quinolin-4-ylmethoxy)-phenyl]-3-methyl-2-oxo-pyrrolidin-1-yl}-propionamide;

2-(3-Amino-3-[4-(2-isopropoxymethyl-quinolin-4-ylmethoxy)-phenyl]-2-oxo-pyrrolidin-1-yl)-4-methyl-pentanoic acid hydroxyamide;

2-(3-Amino-3-[4-(2-isopropoxymethyl-quinolin-4-ylmethoxy)-phenyl]-2-oxo-pyrrolidin-1-yl)-N-hydroxy-propionamide;

LOHRAY ET AL.
Appl. No. Unknown
July 7, 2006

2-(3-Amino-3-{4-[2-(2-methoxy-ethyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-4-methyl-pentanoic acid hydroxyamide;
2-{3-Amino-2-oxo-3-[4-(2-p-tolyl-quinolin-4-ylmethoxy)-phenyl]-pyrrolidin-1-yl}-4-methyl-pentanoic acid hydroxyamide;
2-{3-Amino-2-oxo-3-[4-(2-p-tolyl-quinolin-4-ylmethoxy)-phenyl]-pyrrolidin-1-yl}-N-hydroxy-propionamide;
2-(3-Amino-3-{4-[2-(4-chloro-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-4-methyl-pentanoic acid hydroxyamide;
2-(3-Amino-3-{4-[2-(4-chloro-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-N-hydroxy-propionamide;
2-(3-Amino-3-{4-[2-(4-fluoro-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-4-methyl-pentanoic acid hydroxyamide;
2-(3-Amino-3-{4-[2-(4-fluoro-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-N-hydroxy-propionamide;
2-(3-Amino-3-{4-[2-(4-methoxy-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-4-methyl-pentanoic acid hydroxyamide;
2-(3-Amino-3-{4-[2-(4-methoxy-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-N-hydroxy-propionamide;
N-Hydroxy-2-(3-{4-[2-(4-methoxy-phenyl)-quinolin-4-ylmethoxy]-phenyl}-3-methyl-2-oxo-pyrrolidin-1-yl)-propionamide;
2-(3-Amino-3-{4-[2-(4-ethoxy-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-4-methyl-pentanoic acid hydroxyamide;

LOHRAY ET AL.
Appl. No. Unknown
July 7, 2006

2-(3-Amino-3-{4-[2-(4-ethoxy-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-N-hydroxy-propionamide;

2-(3-Amino-3-{4-[2-(4-benzyloxy-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-4-methyl-pentanoic acid hydroxyamide;

2-(3-Amino-3-{4-[2-(4-benzyloxy-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-N-hydroxy-propionamide;

2-(3-Amino-3-{4-[2-(4-methylsulfanyl-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-4-methyl-pentanoic acid hydroxyamide;

2-(3-Amino-3-{4-[2-(4-methylsulfanyl-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-N-hydroxy-propionamide;

2-{3-Amino-2-oxo-3-[4-(2-m-tolyl-quinolin-4-ylmethoxy)-phenyl]-pyrrolidin-1-yl}-4-methyl-pentanoic acid hydroxyamide;

2-{3-Amino-2-oxo-3-[4-(2-m-tolyl-quinolin-4-ylmethoxy)-phenyl]-pyrrolidin-1-yl}-N-hydroxy-propionamide;

2-(3-Amino-3-{4-[2-(3-chloro-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-4-methyl-pentanoic acid hydroxyamide;

2-(3-Amino-3-{4-[2-(3-chloro-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-N-hydroxy-propionamide;

2-(3-Amino-3-{4-[2-(3-methoxy-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-4-methyl-pentanoic acid hydroxyamide;

2-(3-Amino-3-{4-[2-(3-methoxy-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-N-hydroxy-propionamide;

LOHRAY ET AL.
Appl. No. Unknown
July 7, 2006

2-(3-Amino-3-{4-[2-(5-chloro-thiophen-2-yl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-N-hydroxy-propionamide;
2-(3-Amino-3-{4-[2-(5-methyl-furan-2-yl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-4-methyl-pentanoic acid hydroxyamide;
N-Hydroxy-2-(3-methyl-3-{4-[2-(5-methyl-furan-2-yl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-propionamide;
2-(3-Amino-3-{4-[2-(5-methyl-furan-2-yl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-N-hydroxy-propionamide;
2-{3-Amino-3-[4-(4-methoxymethyl-benzyloxy)-phenyl]-2-oxo-pyrrolidin-1-yl}-4-methyl-pentanoic acid hydroxyamide;
2-{3-Amino-3-[4-(2-methoxymethyl-quinolin-4-ylmethoxy)-phenyl]-2-oxo-pyrrolidin-1-yl}-4-methyl-pentanoic acid;
2-{3-Amino-3-[4-(2-isopropoxymethyl-quinolin-4-ylmethoxy)-phenyl]-2-oxo-pyrrolidin-1-yl}-4-methyl-pentanoic acid;
2-{3-Amino-2-oxo-3-[4-(2-p-tolyl-quinolin-4-ylmethoxy)-phenyl]-pyrrolidin-1-yl}-4-methyl-pentanoic acid;
2-(3-Amino-3-{4-[2-(4-methoxy-phenyl)-quinolin-4-ylmethoxy]-phenyl}-2-oxo-pyrrolidin-1-yl)-propionic acid.

5. (Currently Amended) A pharmaceutical composition, which comprises a compound as defined in ~~claims 1-4~~claim 12, and a pharmaceutically acceptable carrier, diluents or excipients or solvate.

6. (Original) A pharmaceutical composition according to claim 5, in the form of tablets, pills, capsules, powder, granules, syrup, solution or suspension.

7. (Currently Amended) A method for inhibition of production or action of TACE, MMP's and aggrecanase comprising administering a therapeutically acceptable amount of compound of formula (I) as claimed in ~~any preceding claims~~claim 12, or a therapeutically acceptable salt or prodrug thereof.


8. (Currently Amended) A method of treatment or prophylaxis of various inflammatory, infectious, immununological or malignant diseases comprising administering an effective amount of a compound according to ~~any preceding claims~~claim 12 to a mammal including human in need thereof.

9. (Currently Amended) Use of the compounds as claimed in ~~any preceding claims~~claim 12 or their pharmaceutically acceptable salts for the preparation of medicine suitable for the treatment of diseases associated with excess of TNF- α (Tumour Necrosis Factor alpha) production or secretion.


10. (Currently Amended) A medicine for the treatment of diseases associated with excess of TNF- α (Tumour Necrosis Factor alpha) production or secretion comprising the compounds as claimed in ~~claims 1-4~~claim 12, or their pharmaceutically acceptable salts.

11, (Currently Amended) A process for preparing compound of formula (I) as claimed in claim 412, comprising the steps of:


i) converting a compound of formula (2) to a compound of formula (3) where all the symbols are as defined in claim 412




ii) converting a compound of formula (3) to compound of formula (1a), where all symbols are as defined in claim 412




iii) optionally, converting a compound of formula (3) to a compound of formula (4) where all the symbols are as defined in claim 412




iv) converting the compound of formula (4) to further compound formula (1b), where all symbols are as defined earlier




- v) alternatively, compound of formula (3) may optionally be converted to compound of formula (1c), where all symbols are as defined earlier



- vi) alternatively, compound of formula (4) may optionally be converted to compound of formula (1d), where all symbols are as defined earlier



12. (New) Compounds of the general formula (I),



their stereoisomers, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, wherein

A is selected from CO₂H, CONHOH and CONHOR₁.

R_1 represents hydrogen, substituted or unsubstituted groups selected from linear or branched (C_1-C_8) alkyl; R_2 and R_3 may be same or different and independently represent hydrogen, substituted or unsubstituted linear or branched (C_1-C_8) alkyl, groups; X represents optionally substituted phenyl;

Z represents substituted phenyl, quinolinyl, pyrimidinyl groups;

The substituents on Z may be selected optionally from optionally substituted alkoxy alkyl or substituted groups selected from phenyl, or (5-6) membered heterocycle comprising 1-4 heteroatoms selected from the group consisting N, O and S; $n = 1$;

Y represents $(CR'R'')_p$, $O(CR'R'')_p$, $(CR'R'')_pO$, wherein $p = 0-2$; R' and R'' may be same or different and independently represent H, linear or branched substituted or unsubstituted (C_1-C_6) alkyl groups;

R_4 represents H, $NR'R''$, OR' , CN, (C_1-C_6) alkyl; R' and R'' may be same or different and independently represent H, alkyl group, linear or branched substituted or unsubstituted (C_1-C_6) alkyl groups.